Clinical Trials
35 trialsNCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
NCT04964505 2026-02-23
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
University of California, Davis
Phase 1 Terminated
NCT05209295 2026-01-12
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
NCT04937166 2025-11-10
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
Phase 1 Terminated
NCT05168202 2025-09-25
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 1 Terminated
NCT05209152 2025-07-14
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
Phase 1 Terminated
NCT02675452 2025-07-09
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Phase 1 Terminated
NCT05609942 2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03248479 2025-01-17
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Gilead Sciences
Phase 1 Terminated
NCT04755244 2024-11-27
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
ALX Oncology Inc.
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT04172844 2024-06-04
PAVE
Medical College of Wisconsin
Phase 1 Terminated
NCT04336982 2024-05-31
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Celgene
Phase 1 Terminated
NCT04912063 2024-02-26
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
Phase 1 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT02203773 2023-05-16
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT03465540 2023-04-12
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
Phase 1 Terminated
NCT04748848 2023-03-02
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Celgene
Phase 1 Terminated
NCT03217838 2022-04-05
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
AstraZeneca
Phase 1 Terminated
NCT02319369 2021-10-11
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Daiichi Sankyo
Phase 1 Terminated
NCT02750254 2020-10-20
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
Phase 1 Terminated
NCT00234000 2020-07-31
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT01636609 2020-04-13
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT03483948 2019-11-20
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
Hutchmed
Phase 1 Terminated
NCT01957644 2019-02-08
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Boehringer Ingelheim
Phase 1 Terminated
NCT00901537 2018-04-17
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Loma Linda University
Phase 1 Terminated
NCT00443261 2017-02-27
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Kansas Medical Center
Phase 1 Terminated
NCT01886573 2016-11-18
Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01260714 2015-08-20
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated
NCT01167816 2014-05-20
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
University of Oklahoma
Phase 1 Terminated
NCT00923234 2013-12-18
AZALE
Technische Universität Dresden
Phase 1 Terminated
NCT01200004 2013-08-02
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
M.D. Anderson Cancer Center
Phase 1 Terminated